Sanofi
Biotech

Sanofi won't seek approval for eczema drug from Kymab buyout

The French pharma acknowledged that amlitelimab “would not represent a meaningful improvement” to existing treatments.
James Waldron Jul 24, 2026 5:13am
Scribe Therapeutics office in Alameda California

Scribe records upsized $129M IPO to fund genetic med trials

Jul 24, 2026 4:00am
Panther Rare Pharmacy

De-risking rare disease launches: precision beats scale

Brought to you by PANTHERx® Rare Pharmacy
Red flag on a beach with a storm coming

Study reveals genetic red flags for CAR-T therapy side effects

Jul 24, 2026 2:00pm
shutterstock2729915667png

Understanding Agentic AI in Clinical Development

Brought to you by Syneos Health
handshake deal shake hand arrows ok yes
Favicon Fierce Pharma

Merck prepares expanded access to monthly PrEP pill early

Jul 24, 2026 10:40am
More News

Biogen R&D vet gets in Formation—Chutes & Ladders

Jul 24, 2026 8:30am

Scancell heads to Nasdaq via reverse merger with Neuphoria

Jul 23, 2026 10:13am

Lilly triple-G drug hits 22% weight loss, cardio impact unclear

Jul 23, 2026 9:06am

Fierce Biotech Layoff Tracker 2026: Clinuvel, Novartis, & more

Jul 23, 2026 9:00am